Top

Published in:

01-07-2023 | Etanercept | Clinical study

Switching TNF-α inhibitors causes AEs and symptoms related to underlying disease

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Switching tumour necrosis factor (TNF)-α inhibitors may cause injection-site reactions, various other adverse events (AEs), and symptoms related to the underlying disease because of reduced efficacy. These were findings of a study published in BioDrugs . …

Assessment of Reported Adverse Events After Interchanging Between TNF-alpha Inhibitor Biosimilars in the WHO Pharmacovigilance Database BioDrugs : 6 Jun 2023. Available from: URL: https://doi.org/10.1007/s40259-023-00603-8

Title: Switching TNF-α inhibitors causes AEs and symptoms related to underlying disease
Publication date: 01-07-2023
Publisher: Springer International Publishing
Keywords: Etanercept
Adalimumab
Infliximab
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-42068-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Switching TNF-α inhibitors causes AEs and symptoms related to underlying disease

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Trastuzumab

Antineoplastics

Dexamethasone

Multiple drugs

Adalimumab/azathioprine/ceftriaxone

Ondansetron